UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Regulator to consider re-classifying choline alfoscerate as functional food
The Ministry of Food and Drug Safety has requested drugmakers to submit eff...
by Kim Yun-mi
|
2019-11-06 13:54
라인
Merck Korea hurries to close GM part despite union’s protest
Merck Biopharma Korea is stepping up the closure of general medicine (GM) d...
by Kim Yun-mi
|
2019-11-05 15:04
라인
Takeda Korea fires union leader to worsen labor-management dispute
Takeda Pharmaceutical Korea dismissed Kim Young-buk, the leader of Korea De...
by Kim Yun-mi
|
2019-11-04 15:03
라인
Hanyang University Medical Center goes research-centered
“If a hospital focuses only on patient care, it has little chance to grow. ...
by Kim Yun-mi
|
2019-11-01 16:09
라인
Huons’ insomnia cure, 2 other drugs to win insurance benefit
The Ministry of Health and Welfare said it would grant health insurance ben...
by Kim Yun-mi
|
2019-10-31 13:22
라인
AbbVie’s new psoriasis drug likely to win nod this year
AbbVie’s new psoriasis treatment Risankizumab is likely to obtain local lic...
by Kim Yun-mi
|
2019-10-30 16:05
라인
Scope of AI-based medical devices expanded for licensing review
The Ministry of Food and Drug Safety said it would expand the scope of arti...
by Kim Yun-mi
|
2019-10-30 16:03
라인
[Special] Yongin Severance Hospital to go digital with innovation
This is an artist’s rendition of the newly built Yongin Severance Hospital,...
by Kim Yun-mi
|
2019-10-28 15:45
라인
‘Korean hospitals equipped well to use CAR-T therapy’
“CAR-T (chimeric antigen receptor T-cell) therapy has dramatically improved...
by Kim Yun-mi
|
2019-10-23 13:17
라인
Pfizer’s atopic drug should overcome side effects to challenge Sanofi’s Dupixent
Pfizer recently proved the efficacy of its investigational atopic dermatiti...
by Kim Yun-mi
|
2019-10-22 14:17
라인
Merck Korea forcefully shuts down general medicine biz
Merck Biopharma Korea said it would complete shutting down the General Medi...
by Kim Yun-mi
|
2019-10-15 15:51
라인
Galderma Korea’s key strategy: choice and concentration
Galderma recently debuted as the world’s largest independent dermatology co...
by Kim Yun-mi
|
2019-10-15 13:56
라인
[Special] How are Korean employees coping with big-pharma M&As?
Since multinational pharmaceutical companies announced merger and acquisiti...
by Kim Yun-mi
|
2019-10-14 13:45
라인
Sanofi to cover part of Dupixent cost for atopic dermatitis patients
Sanofi said it would run a program to support part of the cost of Dupixent,...
by Kim Yun-mi
|
2019-10-11 15:13
라인
Doctors call Boehringer Ingelheim’s Jardiance marketing ‘unethical’
The medical community criticized Boehringer Ingelheim Korea’s recent releas...
by Kim Yun-mi
|
2019-10-10 16:01
라인
Medtronic Korea denies regulatory negligence over recalled insulin pumps
A group of diabetic patients criticized the local regulator for inadequate ...
by Kim Yun-mi
|
2019-10-08 15:05
라인
Galderma Korea workers feel insecure after separation from Nestle
Galderma has debuted as a rebranded dermatology company after separation fr...
by Kim Yun-mi
|
2019-10-07 14:38
라인
CDK4/6 inhibitor+fulvestrant combo nears getting benefit
The combination therapy of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor ...
by Kim Yun-mi
|
2019-10-02 16:03
라인
‘Merck Korea unilaterally lays off employees’
Merck Biopharma Korea has been embroiled in a labor dispute.Merck Korea bra...
by Kim Yun-mi
|
2019-10-01 11:09
라인
Pfizer’s leukemia therapy Besponsa to get insurance benefit
The government said it would grant insurance benefit to Pfizer’s leukemia t...
by Kim Yun-mi
|
2019-09-26 11:26
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top